Therapies targeting cardiomyocyte metabolism have the potential to complement current heart failure treatments by improving the energetic status of the failing heart.
This review highlights the potential of targeting cardiac metabolism as a complementary approach to current heart failure treatments.
The failing heart has an increased metabolic demand and at the same time suffers from impaired energy efficiency, which is a detrimental combination. Therefore, therapies targeting the energy-deprived failing heart and rewiring cardiac metabolism are of great potential, but are lacking in daily clinical practice. Metabolic impairment in heart failure patients has been well characterized for patients with reduced ejection fraction, and is coming of age in patients with 'preserved' ejection fraction. Targeting cardiomyocyte metabolism in heart failure could complement current heart failure treatments that do improve cardiovascular haemodynamics, but not the energetic status of the heart. In this review, we discuss the hallmarks of normal cardiac metabolism, typical metabolic disturbances in heart failure, and past and present therapeutic targets that impact on cardiac metabolism.
Heggermont et al. (Fri,) conducted a review in Heart failure. Metabolic therapies was evaluated. Therapies targeting cardiomyocyte metabolism have the potential to complement current heart failure treatments by improving the energetic status of the failing heart.